About

William C. Huang, MD, is a professor in the Department of Urology at NYU Grossman School of Medicine and serves as the Vice Chair of Clinical Affairs in the same department. He is also a professor in the Department of Radiology at NYU Grossman School of Medicine. Dr. Huang is the co-director of the Robotic Surgery Center and the chief of the urology service at Tisch Hospital. His clinical practice focuses on urologic oncology, treating patients with kidney cancer, bladder cancer, prostate cancer, testicular cancer, and other cancerous urologic conditions. He has extensive experience performing complex surgical procedures such as radical cystectomy, urinary reconstruction, partial nephrectomy, and radical prostatectomy, utilizing both traditional and advanced minimally invasive and robotic surgical techniques. Dr. Huang's research concentrates on improving quality of life for patients who have undergone surgical treatment for kidney cancer and exploring new treatments for bladder cancer with the aim of curing patients without bladder removal. His expertise and contributions have earned him recognition as one of America’s Top Doctors for Cancer by Castle Connolly, and he has been involved in establishing care guidelines for urinary tract cancers through national and international committees.

Research topics

• Internal medicine
• Medicine
• Oncology
• Computer Science
• Urology
• Artificial Intelligence
• Machine Learning
• Mathematics
• World Wide Web
• Engineering
• Surgery
• Gastroenterology

Selected publications

• UGN-102 for Recurrent Low-Grade Intermediate-Risk Non–Muscle-Invasive Bladder Cancer: A 24-Month Duration of Response Results From the Phase 3 ENVISION Trial

  The Journal of Urology · 2026-03-25

  articleOpen access

  PURPOSE: To report the duration of response to UGN-102 treatment in patients with recurrent low-grade intermediate-risk NMIBC (LG-IR-NMIBC) 24 months after achieving complete response (CR). MATERIALS AND METHODS: ENVISION is an ongoing, multinational, single-arm, phase 3 study in patients with biopsy-proven recurrent LG-IR-NMIBC. Patients received 6 once-weekly intravesical instillations of UGN-102. Patients underwent cystoscopy, urine cytology testing, and for-cause biopsy to determine bladder cancer presence at 3 months. Duration of response (from CR at 3 months to disease recurrence, progression, or death from any cause) at 24 months was estimated using the Kaplan-Meier method. RESULTS: A total of 240 patients were enrolled and received ≥ 1 dose of UGN-102. Most patients were White (98%), male (61%), and aged ≥ 65 years (68%). At 3 months, 191 patients (80%; 95% CI: 74-85) achieved CR. Among these responders, the probability of remaining event-free 24 months after CR was 72% (95% CI: 64-79; Kaplan-Meier estimate). Among patients with CR at 3 months (n = 191), 36 developed LG disease recurrence. Treatment-emergent adverse events that occurred in ≥ 10% of enrolled patients (N = 240) was dysuria. CONCLUSIONS: Patients who achieved CR after UGN-102 treatment had a high probability of remaining event-free 24 months later. These data indicate that UGN-102 is a novel, nonsurgical treatment that provides a durable CR for patients with recurrent LG-IR-NMIBC. Study limitations included the single-arm design and the limited racial diversity of the patients. TRIAL REGISTRATION: ClinicalTrials.gov: NCT05243550.

  PublisherDOI

• Reply by Authors

  The Journal of Urology · 2026-04-29

  article
  PublisherDOI

• Pembrolizumab in Combination With Gemcitabine and Concurrent Hypofractionated Radiation Therapy as Bladder-sparing Treatment for Muscle-invasive Urothelial Cancer of the Bladder: A Multicenter Phase 2 Trial

  European Urology · 2026-04-01

  article
  PublisherDOI

• Cardiac-Gated Diffusion-Weighted Magnetic Resonance Imaging Assessment of Kidney Function in Patients With Kidney Cancer

  Kidney International Reports · 2026-03-11

  articleOpen access

  Background Estimated glomerular filtration rate (eGFR) from serum creatinine outlines global kidney function, subject to biases in clinical scenarios from muscle wasting and inflammation (prevalent in kidney cancer) and failure to estimate split renal function (crucial in operative planning).Measured GFR (mGFR) (or true mGFRt without body surface area normalization) from 99m Tc-DTPA tracer clearance is the gold standard for bilateral kidney function, involving extended clearance times and radioactivity.Imagingderived total kidney volumes are functional proxies, but do not probe tissue quality. MethodsWe employed advanced quantitative diffusion-weighted MRI at 3.0 T in addition to kidney volume measurements in a cohort of 27 renal mass patients (26 and 18 underwent eGFR and mGFR tests, respectively).Cardiac-gated diffusion tensor imaging and intravoxel incoherent motion parameters, were derived.Individual MR metrics were evaluated for correlation with eGFR and mGFR with Pearson correlations and mixed-model analysis, respectively; LASSO-penalized multivariable regression was employed for mGFR prediction.Metrics were compared between proteinuria groups with two-sample ttests.Results Kidney volume correlated with renal function (split volume vs. split mGFR r = 0.54; split volume vs. split mGFRt r = 0.69).MR metrics correlated with individual kidney mGFR and mGFRt (r=0.76 and 0.81, respectively).Mixed-effects LASSO multiple regression analysis predicted mGFR and mGFRt (R 2 = 0.880 and 0.700, respectively).MR metrics also differentiated proteinuria status.Discussion Advanced diffusion-weighted MRI metrics may provide surrogates of mGFR and proteinuria.Parameters from bipolar encoding in diastole (emphasizing tubular flow) and flow compensation in systole (emphasizing vascular flow) were often informative.

  PublisherOA PDFDOI

• Duration of response (DoR) following treatment with UGN-102 in patients with recurrent, low-grade, intermediate-risk, non-muscle invasive, bladder cancer: 18-month DoR data from the phase 3 ENVISION trial.

  Journal of Clinical Oncology · 2025-05-28 · 2 citations

  article

  4598 Background: Low-grade, intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) is a recurrent cancer inadequately controlled by the current standard of care: transurethral resection of bladder tumor (TURBT). ENVISION (NCT05243550), is an ongoing prospective, phase 3, multinational, single-arm trial, evaluating UGN-102 in patients with a history of LG-NMIBC requiring TURBT. Primary efficacy and safety results have been published previously, 1 here we report long term efficacy data with 18 months follow-up after complete response (CR) to UGN-102 at 3 months. Methods: Patients received6 weekly intravesical instillations of UGN-102, a reverse thermal hydrogel containing mitomycin (75 mg). 3 months after the first instillation of UGN-102, patients underwent cystoscopy, urine cytology testing, and for-cause biopsy, to determine the presence or absence of bladder cancer. Secondary endpoints included duration of response (DoR), defined as the time from CR at 3 months to the earliest date of disease recurrence, progression, or death from any cause, whichever occurred first. DoR data was calculated for all patients with a minimum follow-up of 18 months after 3-month CR was calculated using Kaplan–Meier (KM) method. Results: 240 patients with recurrent LG-IR-NMIBC were enrolled and received at least one dose of UGN-102; 95% (228) received all 6 doses. Patients were mainly white (98%), male (61%) and aged over 65 years old (68%). CR at 3 months was achieved by 191 patients (79.6%; 95% CI: 73.9–84.5). For these patients, the probability of remaining in response 18-months after CR was 80.6% (95% CI 74.0-85.7; KM estimate). Of those who experienced recurrence post CR, most experienced LG disease (17.3%). Conclusions: In the ENVISION study treatment with UGN-102 in patients with recurrent LG-IR-NMIBC resulted in a high and clinically meaningful CR rate. Patients who achieved an initial CR at 3 months had a high probability of remaining disease-free 18 months later. This data confirms that UGN-102 represents a valuable treatment option for patients with LG-IR-NMIBC. Clinical trial information: NCT05243550 . UGN-102 CR at 3 months (95% CI) 191/240, 79.6% (73.9–84.5) Follow-up time (months) for DoR, Median, months (95% CI)* 18.73 (18.23–20.27) DoR by Kaplan–Meier estimate at 18 months post CR 80.6% (95% CI 74.0–85.7) Patients with events at 18 months post CR 39/191 (20.4%) LG disease 33/191 (17.3%) Progression** 4/191 (2.1%) Death 2/191 (1.0%) *3-month CR patients only, estimated using reverse KM; ** Includes progression to high grade (HG) disease, T1 (Tumor Invades Lamina Propria), and Cis (Carcinoma in situ). Prasad SM et al. J Urol. 2025. 213:205–216.

  PublisherDOI

• P488 – Artificial intelligence analysis of prostate biopsy stimulated raman histology evaluates peri-tumoral tissue to predict extraprostatic extension of prostate cancer

  European Urology · 2025-03-01

  article
  PublisherDOI

• Does Size Predict Aggressiveness?: Exploring Sporadic Multifocal Tumors in a 10-Year Retrospective Analysis

  Clinical Genitourinary Cancer · 2025-06-18

  articleSenior author
  PublisherDOI

• STIMULATED RAMAN HISTOLOGY AND ARTIFICIAL INTELLIGENCE ALLOWS FOR PREDICTION OF PROSTATE CANCER EXTRAPROSTATIC EXTENSION AND POSITIVE SURGICAL MARGIN DURING RADICAL PROSTECTOMY

  Urologic Oncology Seminars and Original Investigations · 2025-02-27

  article
  PublisherDOI

• Outcomes of endoscopic management for upper tract urothelial carcinoma: A multi-center international cohort analysis

  Urologic Oncology Seminars and Original Investigations · 2025-08-25 · 2 citations

  article
  PublisherDOI

• PRIMARY CHEMOABLATION OF RECURRENT LOW-GRADE INTERMEDIATE-RISK NON-MUSCLE-INVASIVE BLADDER CANCER WITH UGN-102: A SINGLE-ARM, OPEN-LABEL, PHASE 3 TRIAL (ENVISION)

  Urologic Oncology Seminars and Original Investigations · 2025-02-27 · 1 citations

  article
  PublisherDOI

Frequent coauthors

• Samir S. Taneja

  114 shared

• James Wysock

  68 shared

• Herbert Lepor

  63 shared

• Paul Russo

  Memorial Sloan Kettering Cancer Center

  61 shared

• Andrew B. Rosenkrantz

  Health Affairs

  59 shared

• Marc A. Bjurlin

  56 shared

• Fang‐Ming Deng

  NYU Langone Health

  42 shared

• Xiaosong Meng

  The University of Texas Southwestern Medical Center

  34 shared

Labs

• NYU Langone Urologic OncologyPI

Awards & honors

• Named One of America’s Top Doctors for Cancer by Castle Conn…